HC Wainwright Issues Positive Forecast for NMRA Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Research analysts at HC Wainwright lifted their Q2 2026 earnings estimates for Neumora Therapeutics in a report issued on Tuesday, March 31st. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.30) for the quarter, up from their prior forecast of ($0.36). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.29) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($1.10) EPS, FY2029 earnings at ($0.26) EPS and FY2030 earnings at $1.51 EPS.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01).

Several other research analysts have also issued reports on NMRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Neumora Therapeutics in a research note on Tuesday. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Guggenheim reiterated a “buy” rating and set a $14.00 target price on shares of Neumora Therapeutics in a research report on Tuesday. Finally, Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.67.

Neumora Therapeutics Price Performance

Shares of NMRA stock opened at $2.00 on Thursday. The stock’s fifty day simple moving average is $2.74 and its 200 day simple moving average is $2.32. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. The firm has a market cap of $364.08 million, a price-to-earnings ratio of -1.38 and a beta of 3.08. Neumora Therapeutics has a one year low of $0.61 and a one year high of $3.65.

Insiders Place Their Bets

In related news, insider Paul L. Berns sold 9,819 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total transaction of $34,464.69. Following the completion of the sale, the insider directly owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. This trade represents a 0.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 23,387 shares of company stock worth $82,647. Company insiders own 26.80% of the company’s stock.

Institutional Trading of Neumora Therapeutics

Large investors have recently made changes to their positions in the business. Legacy Private Trust Co. boosted its position in Neumora Therapeutics by 35.7% in the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock valued at $34,000 after buying an additional 5,000 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of Neumora Therapeutics by 10.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after acquiring an additional 6,233 shares during the last quarter. Invesco Ltd. raised its position in shares of Neumora Therapeutics by 6.8% during the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after acquiring an additional 8,383 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Neumora Therapeutics during the fourth quarter valued at $27,000. Finally, Virtu Financial LLC acquired a new position in shares of Neumora Therapeutics during the third quarter valued at $31,000. Institutional investors own 47.65% of the company’s stock.

Key Headlines Impacting Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near-term EPS/2026 estimates and reduced projected losses for 2026–2028 (e.g., FY2026 now -$1.29 vs prior -$1.45; Q2/Q3/Q4 2026 trimmed). Improved near‑term visibility can be read as a bullish signal on operational progress. HC Wainwright estimate note
• Positive Sentiment: Brokerage support: Needham reiterated a Buy and Guggenheim issued a Buy; overall broker consensus is a “Moderate Buy” — these endorsements can support investor demand and liquidity. Needham reiterates Buy Guggenheim Buy Consensus Moderate Buy
• Positive Sentiment: Large call-option buying activity was reported, indicating speculative/bullish positioning by traders that can amplify near-term upside volatility. Options activity report
• Neutral Sentiment: Earnings call & roadmap coverage — company held its Q4 2025 call and management outlined upcoming catalysts (development milestones/pipeline priorities). These items set the event calendar but are mixed until concrete clinical or commercial results arrive. Q4 earnings call summary Catalyst roadmap
• Negative Sentiment: Shareholder litigation risk: The Schall Law Firm announced an investigation into possible false/misleading statements — this raises legal and disclosure risk and can pressure the stock while the probe runs. Schall Law Firm investigation
• Negative Sentiment: HC Wainwright cut longer‑term earnings projections (FY2029 and FY2030 lowered materially — FY2029 moved from +$0.07 to -$0.26; FY2030 from $2.02 to $1.51), which tempers the longer‑term upside narrative and could weigh on valuation multiples. HC Wainwright long-term revisions

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.